Hepatocellular carcinoma treatment strategies - a case-based review

Rute Alves, M. Gomes, C. Macedo, H. Miranda, F. Nery
{"title":"Hepatocellular carcinoma treatment strategies - a case-based review","authors":"Rute Alves, M. Gomes, C. Macedo, H. Miranda, F. Nery","doi":"10.5430/JST.V5N2P120","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the fastest growing causes of cancer-related mortality, being mostly diagnosed in patients with cirrhosis. Despite the recent efforts regarding an earlier diagnosis, the majority of patients are at advanced stages at first presentation, when the potential for institution of curative strategies is scarce. This tumor is remarkable because it occurs mostly superimposed on chronic liver diseases, which entails the need to take special attention to liver function preservation and hepatotoxicity prevention when choosing a specific therapy. Major changes had occurred in the management of HCC in the last decade. The decision-making process must be based on an accurate staging of the patient, using the Barcelona Clinic Liver Cancer (BCLC) staging system, updated knowledge of the new therapeutic options, their contraindications and the potential local or systemic complications. The authors start from 4 clinical different scenarios, in order to objectively discuss the therapeutic options available and the decision-making-process based on the staging system.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"54 1","pages":"120"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Solid Tumors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5430/JST.V5N2P120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the fastest growing causes of cancer-related mortality, being mostly diagnosed in patients with cirrhosis. Despite the recent efforts regarding an earlier diagnosis, the majority of patients are at advanced stages at first presentation, when the potential for institution of curative strategies is scarce. This tumor is remarkable because it occurs mostly superimposed on chronic liver diseases, which entails the need to take special attention to liver function preservation and hepatotoxicity prevention when choosing a specific therapy. Major changes had occurred in the management of HCC in the last decade. The decision-making process must be based on an accurate staging of the patient, using the Barcelona Clinic Liver Cancer (BCLC) staging system, updated knowledge of the new therapeutic options, their contraindications and the potential local or systemic complications. The authors start from 4 clinical different scenarios, in order to objectively discuss the therapeutic options available and the decision-making-process based on the staging system.
肝细胞癌的治疗策略-基于病例的回顾
肝细胞癌(HCC)是世界上最常见的肿瘤之一,也是癌症相关死亡率增长最快的原因之一,主要在肝硬化患者中被诊断出来。尽管最近在早期诊断方面做出了努力,但大多数患者在首次出现时已处于晚期,此时建立治疗策略的潜力很少。这种肿瘤是值得注意的,因为它主要是叠加在慢性肝病上,这就需要在选择特定治疗时特别注意肝功能的保护和肝毒性的预防。在过去十年中,HCC的治疗发生了重大变化。决策过程必须基于患者的准确分期,使用巴塞罗那临床肝癌(BCLC)分期系统,对新治疗方案的最新了解,其禁忌症和潜在的局部或全身并发症。作者从临床4种不同的情况出发,客观地讨论了基于分期系统的治疗方案和决策过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信